RESUMO
Preclinical safety of reamberin, a preparation of succinic acid intended for the treatment of patients with shock conditions of different etiology, and remaxol a drug intended for the treatment of patients with liver dysfunction caused by acute intoxication was performed. Both medicines belong to the 5th class of practically non-toxic drugs. Their administration to experimental animals for 30 days did not cause toxic effects on the functional and morphological state of main systems and organs. Both medicines do not affect specific (humoral and cellular) and non-specific immune response and do not cause sensibilization, mutagenic, embryotoxic and teratogenic effects, and also do no alter parameters of reproductive functions of rats.
Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Meglumina/análogos & derivados , Succinatos/efeitos adversos , Succinatos/farmacologia , Animais , Cães , Avaliação Pré-Clínica de Medicamentos , Feminino , Masculino , Meglumina/efeitos adversos , Meglumina/farmacologia , Ratos , Choque/tratamento farmacológicoRESUMO
Cell death is the main element of ischemic-reperfusive states. The balance of main cell death forms (necrosis and apoptosis) in impaired tissues determines the extent of cellular loss and the rate of pathological process spreading, as well as the possibility of functional recovery. The review describes triggering mechanisms of apoptosis under the ischemia-reperfusion conditions, considers the role of inflammation in limiting the cell loss and its dependence on the balance of necrotic and apoptotic forms of cell death at the site of ischemia-reperfusion, and suggests potential methods for pharmacological correction of protective potency of the cell and the balance of cell death forms.
